The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ESH AL 2020 | Molecular profiling to determine treatment for ALL and AML
Oliver Ottmann, MD, FRCPath, University of Cardiff, Cardiff, UK, discusses how molecular profiling and genome sequencing will act as a turning point for deciding treatment options for patients with acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). This is due to prevalent genetic aberrations in these diseases. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJhemOnc).
